サンプル依頼リスト カート
  • English
  • Korean
表紙：呼吸器疾患ワクチンの世界市場レポート 2024年
市場調査レポート
商品コード
1415671

呼吸器疾患ワクチンの世界市場レポート 2024年

Respiratory Disease Vaccine Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
呼吸器疾患ワクチンの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

呼吸器疾患ワクチン市場規模は近年着実に成長しています。2023年の684億米ドルから2024年には699億9,000万米ドルへと、CAGR2.3％で拡大します。歴史的な期間における成長は、呼吸器系疾患の有病率の上昇、ワクチン接種に対する公衆の意識の高まり、公衆衛生への取り組み、効果的で忍容性の高いワクチンへの需要の高まりに起因しています。

呼吸器疾患ワクチンの市場規模は、今後数年間で安定した成長が見込まれます。2028年には年間平均成長率（CAGR）2.1％で761億8,000万米ドルに成長します。予測期間の成長は、高齢化、ヘルスケア支出の増加、ワクチンへの投資、パンデミック対策に起因します。予測期間の主な動向には、革新的ワクチン、共同研究、ワクチン開発の進歩、医薬品承認などが含まれます。

結核患者の増加傾向は、当面の呼吸器疾患ワクチン市場拡大の原動力になると予測されます。結核は、結核菌によって引き起こされる呼吸器疾患の一種であり、主に呼吸器系、特に肺を侵し、他の臓器や身体機能に潜在的な脅威を与え、様々な合併症を引き起こします。結核の罹患率の増加は、呼吸器疾患ワクチンの開発と普及を目指した努力の触媒となる可能性が高いです。これらのワクチンは、結核の感染を軽減する上で極めて重要です。その一例として、世界保健機関（WHO）が2022年10月に発表した「世界結核報告（Global Tuberculosis Report）」のデータによると、2021年の世界の結核罹患数は1,060万人、人口10万人当たりの罹患率は134人と推定されています。これは2020年に報告された1,010万症例から4.5％の増加です。したがって、結核の罹患率の増加は、呼吸器疾患ワクチン市場の成長を牽引する要因になると考えられます。

喫煙率の増加は、呼吸器疾患ワクチン市場の将来的な成長の原動力となる可能性があります。喫煙は、タバコやタバコを含む製品の燃焼から発生する煙を吸ったり吐いたりすることを伴い、気管炎、心臓病、脳卒中、さまざまな形態のがんなど、多くの健康被害をもたらします。呼吸器疾患ワクチンは、喫煙を行う個人に対して、特定の感染症から身を守る手段を提供するという重要な役割を担っています。例えば、2022年7月のカナダ統計局のデータでは、2021年6月と比較してタバコの生産量が5.8％増加したことが強調されています。さらに、タバコの総販売量は2022年5月から1.3％増加し、2022年6月には14億本に達しました。その結果、喫煙率の増加が呼吸器疾患ワクチン市場拡大の原動力となっています。

アジア太平洋は、2023年の呼吸器疾患ワクチン市場において最大の地域でした。北米は予測期間中に最も急成長する地域と予想されます。呼吸器疾患ワクチンレポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の呼吸器疾患ワクチン市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ウイルスワクチン
  • 細菌ワクチン
  • 混合ワクチン
  • 世界の呼吸器疾患ワクチン市場、感染症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • COVID-19
  • インフルエンザ
  • 呼吸器合胞体ウイルス（RSV）
  • 肺炎
  • その他
  • 世界の呼吸器疾患ワクチン市場、年齢別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 幼児
  • 思春期
  • 成人
  • 世界の呼吸器疾患ワクチン市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 診療所
  • 病院
  • その他

第7章 地域および国の分析

  • 世界の呼吸器疾患ワクチン市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の呼吸器疾患ワクチン市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 呼吸器疾患ワクチン市場の競合情勢
  • 呼吸器疾患ワクチン市場企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson Ltd.
    • Merck &Co. Inc.
    • Sanofi SA
    • AstraZeneca PLC

第31章 その他の主要および革新的な企業

  • GlaxoSmithKline PLC
  • Sinovac Biotech Co. Ltd.
  • Moderna Inc.
  • BioNTech SE
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Mitsubishi Tanabe Pharma Corporation
  • Novavax Inc.
  • Emergent BioSolutions Inc.
  • Seqirus
  • Bio Farma
  • Dynavax Technologies Corporation
  • Hualan Biological Bacterin Co. Ltd.
  • Serum Institute of India Pvt. Ltd.
  • Bavarian Nordic A/S

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12270

“Respiratory Disease Vaccine Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory disease vaccine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The respiratory disease vaccine market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
  • 2) By Infection: COVID-19; Influenza; Respiratory Syncytial Virus (RSV); Pneumonia; Other Infections
  • 3) By Age: Infant; Adolescent; Adult
  • 4) By End-User: Clinic; Hospital; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; Merck & Co. Inc.; Sanofi SA; AstraZeneca PLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Respiratory diseases encompass a broad spectrum of conditions that impact the airways and lungs, resulting in respiratory symptoms and compromised breathing. Respiratory disease vaccines, on the other hand, pertain to a category of immunizations specifically formulated to shield individuals from respiratory infections caused by viruses or bacteria that primarily target the respiratory system, which includes the lungs and air passages. These vaccines function by activating the immune system to generate antibodies capable of identifying and combatting the particular pathogens responsible for these diseases.

The primary classifications of respiratory disease vaccines encompass viral vaccines, bacterial vaccines, and combination vaccines. Viral vaccines consist of formulations containing weakened or inactivated viruses. They serve to stimulate immune responses and are instrumental in the prevention of respiratory diseases by instructing the immune system to recognize and mount defenses against distinct viruses. This, in turn, reduces the spread and severity of infections. These vaccines find application in combatting illnesses such as COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, among others, and are administered to individuals spanning various age groups, including infants, adolescents, and adults, within clinical, hospital, and other healthcare settings.

The respiratory diseases vaccine market research report is one of a series of new reports from The Business Research Company that provides respiratory diseases vaccine market statistics, including respiratory diseases vaccine industry global market size, regional shares, competitors with a respiratory diseases vaccine market share, detailed respiratory diseases vaccine market segments, market trends and opportunities and any further data you may need to thrive in the respiratory diseases vaccine industry. This respiratory diseases vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory disease vaccine market size has grown steadily in recent years. It will grow from $68.4 billion in 2023 to $69.99 billion in 2024 at a compound annual growth rate (CAGR) of 2.3%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, growing demand for effective and more tolerable vaccines.

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $76.18 billion in 2028 at a compound annual growth rate (CAGR) of 2.1%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, investments in vaccine, pandemic preparedness. Major trends in the forecast period include innovative vaccines, collaborative research, advancement in vaccine development, drug approval.

The upward trajectory in tuberculosis cases is anticipated to serve as a driving force for the expansion of the respiratory disease vaccine market in the foreseeable future. Tuberculosis (TB) is a form of respiratory disease induced by the bacterium Mycobacterium tuberculosis, primarily afflicting the respiratory system, particularly the lungs, and posing potential threats to other organs and bodily functions, resulting in various complications. The increasing incidence of tuberculosis is likely to catalyze endeavors aimed at developing and disseminating respiratory disease vaccines. These vaccines are pivotal in mitigating the transmission of tuberculosis. As a case in point, data from the Global Tuberculosis Report, as published by the World Health Organization in October 2022, revealed a global tuberculosis (TB) incidence estimated at 10.6 million cases, with a rate of 134 cases per 100,000 population in 2021. This represented a 4.5% increase from the 10.1 million cases reported in 2020. Hence, the mounting incidence of tuberculosis is poised to be a driving factor in the respiratory disease vaccine market's growth.

The increasing prevalence of smoking is poised to be a driving factor in the prospective growth of the respiratory disease vaccine market. Smoking entails the inhalation and exhalation of smoke emanating from the combustion of tobacco or tobacco-containing products, posing a multitude of health hazards, including tracheitis, heart disease, stroke, and various forms of cancer. Respiratory disease vaccines play a crucial role in providing a measure of protection against specific infections for individuals who engage in smoking. For instance, data from Statistics Canada in July 2022 highlighted a 5.8% upsurge in cigarette production compared to June 2021. Additionally, the total volume of cigarettes sold increased by 1.3% from May 2022, reaching a total of 1.4 billion in June 2022. Consequently, the growing incidence of smoking is a driving force behind the expansion of the respiratory disease vaccine market.

The impediment of formulating efficacious vaccines against respiratory viruses serves as a notable constraint on the market's expansion. This challenge is rooted in the perpetually evolving nature of these viruses, necessitating continuous research and development endeavors to keep abreast of emerging strains. Consequently, this dynamic landscape heightens the complexity and cost associated with vaccine development while potentially delaying their accessibility to the general populace. For instance, a March 2023 publication from the National Library of Medicine, a U.S.-based medical library, underscores the challenges encountered in crafting effective respiratory vaccines. This is particularly evident in the case of emerging viruses such as the SARS-associated COVID-19 and avian influenza. These viruses are characterized by a high mutation rate and antigenic variability, amplifying the complexity of vaccine development. Hence, the obstacle of formulating effective vaccines for respiratory viruses represents a hindrance to the growth of the respiratory disease vaccine market.

Leading companies in the respiratory disease vaccine market are committed to the development of innovative products aimed at bolstering their effectiveness, providing advanced solutions for the prevention and treatment of respiratory infections. For instance, in May 2023, Pfizer Inc., a U.S.-based pharmaceutical company, secured approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent vaccine, featuring the respiratory syncytial virus prefusion F (RSVpreF) vaccine, is designed for the prevention of lower respiratory tract disease stemming from respiratory syncytial virus in individuals aged 60 years and above. ABRYSVO comprises unadjuvanted vaccine components, with two preF proteins meticulously tailored to optimize immunity against both RSV A and B strains. Clinical trials have demonstrated the vaccine's safety and efficacy.

In August 2022, GSK PLC, a biopharmaceutical company headquartered in the UK, completed the acquisition of Affinivax Inc. The financial details of the acquisition were not disclosed. This strategic move reaffirms GSK Plc's dedication to innovation in the realm of pharmaceuticals and vaccines, including its commitment to the development of a next-generation 24-valent pneumococcal vaccine candidate known as AFX3772. Affinivax Inc., a clinical-stage biotechnology company based in the United States, specializes in the development of vaccines and immunotherapies targeted at a range of diseases, with a particular focus on respiratory ailments.

Major players in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the respiratory diseases vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory diseases vaccine market consists of sales of the rotavirus vaccine, bordetella vaccine and varicella (chickenpox) vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Respiratory Disease Vaccine Market Characteristics

3. Respiratory Disease Vaccine Market Trends And Strategies

4. Respiratory Disease Vaccine Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Respiratory Disease Vaccine Market Size and Growth

  • 5.1. Global Respiratory Disease Vaccine Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Respiratory Disease Vaccine Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Respiratory Disease Vaccine Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Respiratory Disease Vaccine Market Segmentation

  • 6.1. Global Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Viral Vaccine
  • Bacterial Vaccine
  • Combination Vaccine
  • 6.2. Global Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • COVID-19
  • Influenza
  • Respiratory Syncytial Virus (RSV)
  • Pneumonia
  • Other Infections
  • 6.3. Global Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Infant
  • Adolescent
  • Adult
  • 6.4. Global Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Clinic
  • Hospital
  • Other End-Users

7. Respiratory Disease Vaccine Market Regional And Country Analysis

  • 7.1. Global Respiratory Disease Vaccine Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Respiratory Disease Vaccine Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Respiratory Disease Vaccine Market

  • 8.1. Asia-Pacific Respiratory Disease Vaccine Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Respiratory Disease Vaccine Market

  • 9.1. China Respiratory Disease Vaccine Market Overview
  • 9.2. China Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Respiratory Disease Vaccine Market

  • 10.1. India Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Respiratory Disease Vaccine Market

  • 11.1. Japan Respiratory Disease Vaccine Market Overview
  • 11.2. Japan Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Respiratory Disease Vaccine Market

  • 12.1. Australia Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Respiratory Disease Vaccine Market

  • 13.1. Indonesia Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Respiratory Disease Vaccine Market

  • 14.1. South Korea Respiratory Disease Vaccine Market Overview
  • 14.2. South Korea Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Respiratory Disease Vaccine Market

  • 15.1. Western Europe Respiratory Disease Vaccine Market Overview
  • 15.2. Western Europe Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Respiratory Disease Vaccine Market

  • 16.1. UK Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Respiratory Disease Vaccine Market

  • 17.1. Germany Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Respiratory Disease Vaccine Market

  • 18.1. France Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Respiratory Disease Vaccine Market

  • 19.1. Italy Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Respiratory Disease Vaccine Market

  • 20.1. Spain Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Respiratory Disease Vaccine Market

  • 21.1. Eastern Europe Respiratory Disease Vaccine Market Overview
  • 21.2. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Respiratory Disease Vaccine Market

  • 22.1. Russia Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Respiratory Disease Vaccine Market

  • 23.1. North America Respiratory Disease Vaccine Market Overview
  • 23.2. North America Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Respiratory Disease Vaccine Market

  • 24.1. USA Respiratory Disease Vaccine Market Overview
  • 24.2. USA Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Respiratory Disease Vaccine Market

  • 25.1. Canada Respiratory Disease Vaccine Market Overview
  • 25.2. Canada Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Respiratory Disease Vaccine Market

  • 26.1. South America Respiratory Disease Vaccine Market Overview
  • 26.2. South America Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Respiratory Disease Vaccine Market

  • 27.1. Brazil Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Respiratory Disease Vaccine Market

  • 28.1. Middle East Respiratory Disease Vaccine Market Overview
  • 28.2. Middle East Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Respiratory Disease Vaccine Market

  • 29.1. Africa Respiratory Disease Vaccine Market Overview
  • 29.2. Africa Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Respiratory Disease Vaccine Market Competitive Landscape And Company Profiles

  • 30.1. Respiratory Disease Vaccine Market Competitive Landscape
  • 30.2. Respiratory Disease Vaccine Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi SA
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca PLC
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Respiratory Disease Vaccine Market Other Major And Innovative Companies

  • 31.1. GlaxoSmithKline PLC
  • 31.2. Sinovac Biotech Co. Ltd.
  • 31.3. Moderna Inc.
  • 31.4. BioNTech SE
  • 31.5. CSL Limited
  • 31.6. Daiichi Sankyo Company Limited
  • 31.7. Mitsubishi Tanabe Pharma Corporation
  • 31.8. Novavax Inc.
  • 31.9. Emergent BioSolutions Inc.
  • 31.10. Seqirus
  • 31.11. Bio Farma
  • 31.12. Dynavax Technologies Corporation
  • 31.13. Hualan Biological Bacterin Co. Ltd.
  • 31.14. Serum Institute of India Pvt. Ltd.
  • 31.15. Bavarian Nordic A/S

32. Global Respiratory Disease Vaccine Market Competitive Benchmarking

33. Global Respiratory Disease Vaccine Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Respiratory Disease Vaccine Market

35. Respiratory Disease Vaccine Market Future Outlook and Potential Analysis

  • 35.1 Respiratory Disease Vaccine Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Respiratory Disease Vaccine Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Respiratory Disease Vaccine Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer